2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Acute Myeloid Leukemia With Minimal Differentiation
National Cancer Institute (NCI)Small moleculePhase 3Dormant
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acute Myeloid Leukemia With Minimal Differentiation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Etoposide Stanford University | Phase 3 | BBB |
Cytarabine Northwestern University | Phase 3 | BBB |
Daunomycin National Cancer Institute (NCI) | Phase 3 | BBB |
Idarubicin Bruno C. Medeiros | Phase 2 | BBB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →